shows widespread disability in ultrastructure and ciliary motility where it affects the impaired function of movement and clearance of cilia.
then stopped taking his medication because he feel no improvement. He had a history of colds, nasal congestion, and heart abnormalities since childhood. Patient did not go to doctor because symptoms resolve after taking self-purchased drugs. On general examination patient is anaemic with grade 2 clubbing, cyanosis, no pallor, icterus and pedal edema. His pulse was 122x/mins regular, respiratory pressure 120/80 mmHg in right arm supine position and oxygen saturation 90,7% with NRBM 10 lpm. On cardiovascular examination, apex beat was felt on right 5th intercostals space 1 cm lateral to midclavicular line and on auscultation of heart, heart sound better heard on right side with no murmur and gallop sign. Abdominal examination obtained tympanic note on percussion in right hypochondrium. X-Ray shows bronchiectasis. HRCT shows that patient had dextrocardia with opposite visceral abdomen. Waters x-ray shows that patient had a sinusitis on frontalis sinistra and sinus maxilaris bilateral. All these things lead to Kartagener's Syndrome.
Conclusion:
The available information on various aspect of this disease in order to delineate the therapeutic objective more clearly. Early diagnosis is important for maintain of pulmonary function, quality of life, and increase in life expectancy in this disease. Results: 48 patients were screened and 43 patients (90%) were assessed. 21 patients were assigned to cefepime group and 22 were piperacillin/tazobactam group. APACHE II score were 18.7 AE 7.2 and 19.7 AE 7.9 (P = 0.67). Clinical success rates were 86% and 82% for patients treated with cefepime and piperacillin/tazobactam, respectively and 3 (14%) and 4 patients (18%) were died. Also there were no statistical significance in terms of frequency of concomitant antibiotics, antibiotics duration, numbers, duration of mechanical ventilation and MICU days. Pretreatment organisms were P. aeruginosa 3, Acinetobacter spp. 2, K. pneumoniae 1, S. pneumoniae 1, coagulase negative staphylococcus 1, methicillin-sensitive staphylococcus aureus 1, and M. pneumoniae 1. 9 patients (43%) in cefepime group and 5 (23%) in piperacillin/tazobactam group were superinfected (P = 0.08). Costs of cefepime group was $ 1165 AE 199, and that of piperacillin/tazobactam group was $ 893 AE 152 (P = 0.28).
Conclusion: There were no significant differences in clinical efficacy and cost-effectiveness in both groups. They would be acceptable strategies in terms of mortality but have concerns for superinfection and cost. has target treatment and lower toxicity. But, nebulized based therapy has high risk for failure of concurrent CRAB blood infection. We studied efficacy and problem intravenous (IV) and intravenous with nebulized colistin (IVNE) Methods: We reviewed sixty patients with VAP caused CRAB. They treated with either intravenous ((IV, n = 42) and intravenous with nebulized colistin (IVNE, n = 18). We enrolled patients from January 2015 to December 2016 in Gachon University Gil Medical Center. We analyzed this patient based on medical record, retrospectively.
Results: Of 60 patients, eighteen patients were treated intravenous colistin with concurrent nebulized colistin (IVNE) and 42 patients were treated only intravenous colistin (IV). Of 60 years patients, Blood of seven patients cultured CRAB. All patients were IV group. There was no CRAB in blood of IVNE. Mortality rate of IVNE and IV were 33.3% and 61.9%
and was statistically significant (P = 0.042). In IVNE group, length of colistin treatment was statistically significant longer (P = 0.008). But Day from admission to colitin treatment was significant lower (P = 0.012). There were no statically significant difference in acute renal failure and increased BUN/Cr.
In this study, we suggest that concurrent intravenous colistin therapy with nebulized colistin may be safe and effective treatment compared with only intravenous colistin. 
